- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
39065-95-7
C7H6ClF2NO
193.58
1.402±0.06
Pale yellow
Philadelphia chromosome-positive chronic myeloid leukemia
Asciminib
5/14/2040 (Asciminib)
ABL/BCR-ABL1 tyrosine kinase
DESCRIPTION
As a novel BCR-ABL inhibitor, Asciminib offers a highly targeted therapy that tackles CML with remarkable efficacy and improved safety profile. With its innovative mechanism of action and potential to overcome resistance mutations, Asciminib represents a significant advancement in the management of CML. By incorporating Asciminib into your pharmaceutical portfolio, you can empower patients with this innovative and life-changing treatment option. Join the fight against CML with Asciminib and make a lasting impact on patient care.
